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cillinMICs≤2 and≤0.06g/ml indicates amoxicillin and ampicillin
susceptibility, respectively. Serotype 19A made up 72% of drug
resistant clinical isolates and almost half of 19A clinical isolates
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Background: Rotavirus is the leading cause of acute gastroen-
eritis in infants worldwide. RotaTeqTM is approved for preventing
otavirus gastroenteritis in infants in many countries; this is the
rst study of RotaTeqTM in China.
Methods: Randomized (1:1), placebo-controlled, double-blind,
ingle site study in Chinese adults (19-47 years, Cohort I), children
2-6 years, Cohort II), and infants (6-12 weeks for ﬁrst dose, Cohort
II). Cohorts I and II received 1 dose (RotaTeqTM or placebo); Cohort
II received 3 doses at 4-10week intervalswith the 3rd dose admin-
stered by 32 weeks of age. The objective was to assess vaccine
afety. Participants were followed for adverse events (AEs) includ-
ng elevated temperature, vomiting, and diarrhea through 14 days
fter any dose. Serious adverse events (SAEs), deaths, and intus-
usception were collected throughout the study. In Cohort III, two
tool sampleswere collected 3-7 days following each dose to assess
accine-virus shedding.
Results: A total of 144 subjects (48 per cohort) were random-
zed and vaccinated. In Cohorts I and II, no SAEs were reported. In
ohort III, no vaccine recipients experienced a SAE; 3/24 (12.5%)
lacebo recipients reported 4 SAEs. In Cohort III, the most com-
only reported non-serious AEs (NSAEs), were diarrhea [54.2%
13/24) in vaccine group, 33.3% (8/24) in placebo group], vomit-
ng [37.5% (9/24) in vaccine group, 50.0% (12/24) in placebo group],
nd pyrexia [37.5% (9/24) in vaccine group, 20.8% (5/24) in placebo
roup]. The NSAEs were mostly mild or moderate in intensity and
esolved or were resolving by the end of the study. In Cohort III,
he numbers of subjects with fecal vaccine-virus shedding (stool
ositive for rotavirus by EIA and conﬁrmed as vaccine-strain by
P6 PCR, which measures intact and degraded particles) were 3/23
13.0%) postdose 1, 2/21 (9.5%) postdose 2, and 3/22 (13.6%) post-
ose 3.
Conclusion: RotaTeqTM was generally well-tolerated in healthy
hinese adults, children and infants. The overall safety and fecal
accine-virus shedding observed in this study were generally com-
arable to results seen in larger studies conducted outside China.
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Background: A 7-valent pneumococcal conjugate vaccine
(PCV7) was approved for use in Canada in June 2001, but was not
fully implemented in Ontario until 2005. To evaluate the impact of
PCV7 vaccination on prevalence, serotype and antimicrobial resis-
tance patterns of Streptococcus pneumoniae, we conductedactive
surveillancefor IPD cases in children of Ontario in Canada with 5
years old and under.
Methods: IPD has been a reportable disease in Ontario since
2001. Provincial datawereobtainedbycompiling laboratory results
fromthePublicHealthOntario Laboratories (PHOL) and theToronto
Invasive Bacterial Disease Network (TIBDN). Clinical isolates were
serotyped by Quellung reaction. Broth microdilution methods are
used for antimicrobial susceptibility testing according to 2011 CLSI
guidelines.
Results: In total 295 IPD cases (73, 63, 70, 35 and 54 respec-
tively from 2007 to 2011) were observed. Overall PCV7 serotypes
decreased gradually in the post-PCV7 era. However, the number of
cases caused by several non-PCV7 serotypes increased: 19A, 7F,
3 and 22F (Figure). Serotype 19A remained the most predomi-
nant type, with an increase from 30% to 42% during 2007-2009,
and 22% during 2010-2011. Serotype 7F increased to 20% in 2011.
29.4% of all clinical isolates were resistant to one or more antibi-
otics (n =146, 2007-9 isolates). Of all isolates, the rate ofmulti-drug
resistance and penicillin non-susceptibility were 25% and 11.6%
respectively. 2 penicillin susceptible isolates were shown to be
amoxicillin nonsusceptible (intermediate,MIC=4g/ml). This is of
clinical relevance, as the current CLSI guidelines advise that peni-
